Peter Libby, MD
Cardiovascular Disease · Boston, MANPI 1033161401
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $39,472 of the $42,735 with a category attached, or 92.4%. 14 manufacturers reported payments, led by Novartis Pharma AG at 35.4% of the total. Reporting peaked in 2019 at $18,311 and has fallen 89.4% since, to $1,933 in 2025.
Across 67 payments — averaging $637.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Pharma AG$15K
- Novo Nordisk AS$9K
- Regeneron$7K
- Abbott$4K
- Amgen$3K
- Merck$1K
- plus $3K from 8 others
Across 4 payments — averaging $196,588 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$502K
- Novartis Pharma AG$214K
- Novo Nordisk AS$70K
What the payments were for
- Speaking & faculty fees$9582%
- Travel & lodging$39,47292%
- Food & beverage$2,3055%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Pharma AG | 10 | $15,107 |
| Novo Nordisk AS | 3 | $9,371 |
| Regeneron | 11 | $7,436 |
| Abbott | 4 | $3,640 |
| Amgen | 17 | $3,266 |
| Merck | 10 | $1,225 |
| CSL Behring | 2 | $1,034 |
| KOWA Company, LTD. | 1 | $958 |
| Esperion Therapeutics, Inc. | 2 | $194 |
| Genentech, Inc. | 2 | $180 |
| Kowa Pharmaceuticals America, Inc. | 2 | $152 |
| AbbVie | 1 | $75 |
| Novartis | 1 | $71 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LCZ696_ENTRESTO_CARDIOVASCULAR$7,638
- ACZ885M_ILARIS_IMMUNOLOGY$7,638
- RLX030A_INVESTIGATIONAL_CARDIOVASCULAR$7,638
- LIK066X_INVESTIGATIONAL_CARDIOVASCULAR$7,638
- ENTRESTO$7,288
- PRALUENT$6,884
- AMPLATZER$3,572
- Livalo$116
- NEXLETOL$107
How this compares
$42,735 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.